High-dimensional immune phenotyping of blood cells by mass cytometry in patients infected with hepatitis C virus.

Détails

Ressource 1Télécharger: CMI_Herderschee.pdf (2765.02 [Ko])
Etat: Public
Version: Author's accepted manuscript
Licence: Non spécifiée
ID Serval
serval:BIB_300AF1BADC64
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
High-dimensional immune phenotyping of blood cells by mass cytometry in patients infected with hepatitis C virus.
Périodique
Clinical microbiology and infection
Auteur⸱e⸱s
Herderschee J., Heinonen T., Fenwick C., Schrijver I.T., Ohmiti K., Moradpour D., Cavassini M., Pantaleo G., Roger T., Calandra T.
Collaborateur⸱rice⸱s
Swiss HIV Cohort Study
Contributeur⸱rice⸱s
Aebi-Popp K., Anagnostopoulos A., Battegay M., Bernasconi E., Böni J., Braun D.L., Bucher H.C., Calmy A., Cavassini M., Ciuffi A., Dollenmaier G., Egger M., Elzi L., Fehr J., Fellay J., Furrer H., Fux C.A., Günthard H.F., Haerry D., Hasse B., Hirsch H.H., Hoffmann M., Hösli I., Huber M., Kahlert C.R., Kaiser L., Keiser O., Klimkait T., Kouyos R.D., Kovari H., Ledergerber B., Martinetti G., Martinez de Tejada B., Marzolini C., Metzner K.J., Müller N., Nicca D., Paioni P., Pantaleo G., Perreau M., Rauch A., Rudin C., Scherrer A.U., Schmid P., Speck R., Stöckle M., Tarr P., Trkola A., Vernazza P., Wandeler G., Weber R., Yerly S.
ISSN
1469-0691 (Electronic)
ISSN-L
1198-743X
Statut éditorial
Publié
Date de publication
04/2022
Peer-reviewed
Oui
Volume
28
Numéro
4
Pages
611.e1-611.e7
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: ppublish
Résumé
Chronic hepatitis C virus (HCV) infection affects the immune system. Whether elimination of HCV with direct-acting antivirals (DAA) restores immunity is unclear. We used mass cytometry to get a broad and in-depth assessment of blood cell populations of patients with chronic HCV before and after DAA therapy.
Before and 12 weeks after sustained virological response (SVR12) to DAA therapy, 22 cell populations were analysed by mass cytometry in blood collected from ten healthy control individuals and 20 HCV-infected patients with (ten patients) or without (ten patients) human immunodeficiency virus (HIV) infection.
HCV infection altered the frequency of 14/22 (64%) blood cell populations. At baseline, the frequencies (median, interquartile range (IQR); control, HCV, HCV/HIV) of intermediate monocytes (1.2, IQR 0.47-1.46; 1.76, IQR 0.83-2.66; 0.78, IQR 0.28-1.77), non-classical monocytes (1.11, IQR 0.49-1.26; 0.9, IQR 0.18-0.99; 0.54, IQR 0.28-1.77), conventional dendritic cells type 2 (0.55, IQR 0.35-0.59; 0.31, IQR 0.16-0.38; 0.19, IQR 0.11-0.36) and CD56 <sup>dim</sup> natural killer cells (8.08, IQR 5.34-9.79; 4.72, IQR 2.59-6.05) 3.61, IQR 2.98-5.07) were reduced by 35% to 65%, particularly in HCV/HIV co-infected patients. In contrast, activated double-negative T cells (0.07, IQR 0.06-0.10; 0.10, IQR 0.09-0.19; 0.19, IQR 0.12-0.25), activated CD4 T cells (0.28, IQR 0.21-0.36; 0.56, IQR 0.33-0.77; 0.40, IQR 0.22-0.53) and activated CD8 T cells (0.23, IQR 0.14-0.42; 0.74, IQR 0.30-1.65; 0.80, IQR 0.58-1.16) were increased 1.4 to 3.5 times. Upon stimulation with Toll-like receptor ligands, the expression of cytokines was up-regulated in 7/9 (78%) and 17/19 (89%) of the conditions in HCV- and HCV/HIV-infected patients, respectively. Most alterations persisted at SVR12.
Chronic HCV and HCV/HIV infections induce profound and durable perturbations of innate and adaptive immune homeostasis.
Mots-clé
Antiviral Agents/therapeutic use, CD8-Positive T-Lymphocytes, HIV Infections/complications, HIV Infections/drug therapy, Hepacivirus, Hepatitis C/complications, Hepatitis C/drug therapy, Hepatitis C, Chronic/drug therapy, Humans, Adaptive immunity, Direct-acting antiviral therapy, Hepatitis C virus, Human immunodeficiency virus, Innate immunity, Mass cytometry, Single cell
Pubmed
Web of science
Open Access
Oui
Financement(s)
SNF/Programs/147662 SNF/Projects/310030_173123 EC/H2020/676129 OTHER//Société Académique Vaudoise
Création de la notice
04/10/2021 13:55
Dernière modification de la notice
30/03/2023 6:53
Données d'usage